IDH2 and neoplasm: As IDH1 and IDH2 mutations occur early in the evolution of the disease [12, 14, 15, 16] and appear to be retained if the tumour transforms into higher grade disease [14], we considered that they could be exploited as biomarkers for clinical outcome.